Aprepitant, a novel neurokinin-1 receptor antagonist in management of chemotherapy induces nausea vomiting (CINV) in cancer patients

Abstract

Nausea and emesis are two major concerns for patients undergoing chemotherapy for cancer. The 5HT3 receptors antagonist ondansetron is the major factor for preventing and treatment for CINV either alone or often is combination with dexamethasone. Even these treatment options exist, CINV remind as major adverse event for all chemotherapeutic agents. The adverse events have major impact on patients quality of life and compliance with treatment. Aprepitant, a novel neurokinin-1 (NK-1) antagonist has been introduced as a new class of drug to prevent CINV. Many trials and studies reveals that comparison of aprepitant to the standard ondansetron and dexamethasone is superior in protecting against CINV. Here this study evaluate and reveals the use and benefits of aprepitant in the management of CINV.